NEMLUVIO data show sustained three‑year responses in atopic dermatitis

Data ReadoutpositiveNEMLUVIOPositive

AI Analysis

Summary

NEMLUVIO demonstrated sustained three-year efficacy responses in atopic dermatitis and prurigo nodularis, reinforcing its therapeutic potential across these dermatological conditions.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

sustained three-year responses in atopic dermatitis and prurigo nodularis

Importance:6/10

Sentiment:

0.75

atopic dermatitisprurigo nodularislong-term dataclinical efficacy

Related Companies

$GDERF

Read the original article

Published by PharmaTimes on October 14, 2026 9:36 AM

Read Original